This inventor holds 1 USPTO granted patent. Top assignee: National Dong Hwa University. Active years: 2019.
Company Filing History:
Years Active: 2019
Title: The Innovative Contributions of Ming-Kai Weng
Introduction
Ming-Kai Weng is a notable inventor based in Hualien, Taiwan. He has made significant contributions to the field of pharmaceuticals, particularly in cancer treatment. His work focuses on the development of novel compounds that can serve as effective inhibitors for cancer-related enzymes.
Latest Patents
Ming-Kai Weng holds a patent for a groundbreaking invention titled "Scalarane sesterterpenoid, pharmaceutical composition and topoisomerase II and Hsp90 inhibitor for treating cancer, and use and preparation method thereof." This patent discloses scalarane sesterterpenoids represented by specific formulas, which are extracted from sponge species. The compounds developed can act as anticancer agents, targeting topoisomerase II and Hsp90, thus providing a new avenue for cancer treatment. He has 1 patent to his name.
Career Highlights
Ming-Kai Weng is affiliated with National Dong Hwa University, where he engages in research and development in the field of pharmaceuticals. His academic background and research initiatives have positioned him as a key figure in the study of cancer therapies.
Collaborations
Ming-Kai Weng has collaborated with notable colleagues such as Mei-Chin Lu and Ping-Jyun Sung. Their combined expertise enhances the research efforts in developing innovative cancer treatments.
Conclusion
Ming-Kai Weng's contributions to pharmaceutical innovation, particularly in cancer treatment, highlight the importance of research and collaboration in advancing medical science. His work continues to inspire future developments in the field.